Скачать или смотреть Deciding between upfront transplant versus a targeted approach in newly diagnosed MCL

Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the evolving treatment paradigm for frontline mantle cell lymphoma (MCL), highlighting the impact of recent clinical trials on the decision between upfront stem cell transplantation (SCT) and targeted therapy approaches. Dr Shah explains that the use of BTK inhibitors (BTKi) as part of induction and maintenance has demonstrated encouraging outcomes, and that measurable residual disease (MRD) status is now a key factor in determining whether a patient should proceed to transplant following frontline BTKi therapy. This interview took place virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.